| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.NBD.2008.07.001 |
| P932 | PMC publication ID | 3643980 |
| P698 | PubMed publication ID | 18675357 |
| P5875 | ResearchGate publication ID | 23144687 |
| P4011 | Semantic Scholar paper ID | 6ee34e683d39f79add962b6f404b889b028275f5 |
| P50 | author | Beate Ritz | Q62506980 |
| Shannon L Rhodes | Q67212276 | ||
| P2860 | cites work | Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism | Q77747967 |
| Screening of ferritin light polypeptide 460-461InsA mutation in Parkinson's disease patients in North America | Q78594759 | ||
| Age at menopause predicts age at onset of Parkinson's disease | Q79212192 | ||
| The 5'-untranslated region of Parkinson's disease alpha-synuclein messengerRNA contains a predicted iron responsive element | Q79838827 | ||
| Midbrain iron content in early Parkinson disease: a potential biomarker of disease status | Q80437646 | ||
| The transferrin homologue, melanotransferrin (p97), is rapidly catabolized by the liver of the rat and does not effectively donate iron to the brain | Q80832800 | ||
| Association study of the G258S transferrin gene polymorphism and Parkinson's disease in the Spanish population | Q80941796 | ||
| Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis | Q22242250 | ||
| Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease | Q22251216 | ||
| Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes | Q22337213 | ||
| LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity | Q24290410 | ||
| Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein | Q24292317 | ||
| Stromal cell-derived receptor 2 and cytochrome b561 are functional ferric reductases | Q24294781 | ||
| Interleukin-6 induces hepcidin expression through STAT3 | Q24296906 | ||
| Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis | Q24305495 | ||
| Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization | Q24310115 | ||
| Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression | Q24316099 | ||
| Severe iron deficiency anemia in transgenic mice expressing liver hepcidin | Q24536163 | ||
| Identification of a novel iron-responsive element in murine and human erythroid delta-aminolevulinic acid synthase mRNA | Q24561404 | ||
| IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin | Q24568204 | ||
| A cytosolic protein binds to structural elements within the iron regulatory region of the transferrin receptor mRNA | Q24614690 | ||
| alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies | Q24653247 | ||
| Modulation of metal-induced genotoxicity by Maillard reaction products isolated from coffee | Q74830250 | ||
| Expression of iron transport proteins and excessive iron accumulation in the brain in neurodegenerative disorders | Q77208531 | ||
| Expression of hepcidin is down-regulated in TfR2 mutant mice manifesting a phenotype of hereditary hemochromatosis | Q38516501 | ||
| Dietary factors in Parkinson's disease: the role of food groups and specific foods | Q38547790 | ||
| Occupational exposures to metals as risk factors for Parkinson's disease | Q39441603 | ||
| Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones | Q39615110 | ||
| Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson's disease accelerate age-related neurodegeneration. | Q40114497 | ||
| Screening for mutations of the HFE gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra | Q40293900 | ||
| Altered brain metabolism of iron as a cause of neurodegenerative diseases? | Q40391355 | ||
| Efficient transfer of receptor-associated protein (RAP) across the blood-brain barrier | Q40512598 | ||
| Diferric transferrin regulates transferrin receptor 2 protein stability | Q40524098 | ||
| Iron acquisition and expression of iron regulatory proteins in the developing brain: manipulation by ethanol exposure, iron deprivation and cellular dysfunction | Q40537938 | ||
| Multiple risk factors for Parkinson's disease | Q40539898 | ||
| Alpha-synuclein up-regulation and aggregation during MPP+-induced apoptosis in neuroblastoma cells: intermediacy of transferrin receptor iron and hydrogen peroxide | Q40595894 | ||
| The enigma of neuromelanin in Parkinson's disease substantia nigra | Q40608849 | ||
| Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier. | Q40969107 | ||
| Alpha-synuclein in Lewy bodies | Q27860680 | ||
| A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload | Q28139987 | ||
| A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation | Q28140006 | ||
| Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo | Q28140681 | ||
| An iron-regulated ferric reductase associated with the absorption of dietary iron | Q28202796 | ||
| Iron-dependent regulation of the divalent metal ion transporter | Q28210422 | ||
| Regulation of the 75-kDa subunit of mitochondrial complex I by iron | Q28213601 | ||
| High transcytosis of melanotransferrin (P97) across the blood-brain barrier | Q28214157 | ||
| Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway | Q28214714 | ||
| Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat | Q28215248 | ||
| Cloning and characterization of a mammalian proton-coupled metal-ion transporter | Q28245045 | ||
| Oxidative stress in neurodegeneration: cause or consequence? | Q28275946 | ||
| Recombinant expression and functional characterization of human hephaestin: a multicopper oxidase with ferroxidase activity | Q28280732 | ||
| Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration | Q28281967 | ||
| Identification of the iron-responsive element for the translational regulation of human ferritin mRNA | Q28302958 | ||
| Receptor-mediated transcytosis of transferrin across the blood-brain barrier | Q28303216 | ||
| Expression of the iron transporter ferroportin in synaptic vesicles and the blood-brain barrier | Q28507937 | ||
| Slc11a2 is required for intestinal iron absorption and erythropoiesis but dispensable in placenta and liver | Q28509001 | ||
| Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice | Q28510424 | ||
| Identification of an intestinal heme transporter | Q28513323 | ||
| Identification of differentially expressed genes in response to dietary iron deprivation in rat duodenum | Q28575734 | ||
| Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice | Q28586797 | ||
| A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression | Q28590840 | ||
| Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells | Q28594532 | ||
| Epidemiology of Parkinson's disease | Q29614901 | ||
| Balancing acts: molecular control of mammalian iron metabolism | Q29620380 | ||
| The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation | Q29620394 | ||
| Are men at greater risk for Parkinson's disease than women? | Q30433122 | ||
| Dopaminergic cell death induced by MPP(+), oxidant and specific neurotoxicants shares the common molecular mechanism | Q31961819 | ||
| Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings | Q33182444 | ||
| Association of HFE common mutations with Parkinson's disease, Alzheimer's disease and mild cognitive impairment in a Portuguese cohort | Q33249091 | ||
| Seleno-L-methionine protects against beta-amyloid and iron/hydrogen peroxide-mediated neuron death | Q33272194 | ||
| Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson's disease: implications for idiopathic and monogenetic forms | Q33283198 | ||
| Heme oxygenase: recent advances in understanding its regulation and role. | Q33750898 | ||
| Cloning of the cDNA encoding an RNA regulatory protein--the human iron-responsive element-binding protein | Q33842468 | ||
| Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients | Q33861614 | ||
| Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. | Q33922930 | ||
| Effect of tea and other dietary factors on iron absorption | Q34058571 | ||
| Receptor-mediated endocytosis of transferrin at the blood-brain barrier | Q34062024 | ||
| Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease | Q34083035 | ||
| Impaired iron homeostasis in Parkinson's disease. | Q34155212 | ||
| Protein damage and degradation by oxygen radicals. I. general aspects | Q34163421 | ||
| Inhibition of food iron absorption by coffee | Q34259075 | ||
| Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium | Q34388931 | ||
| Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. | Q34464847 | ||
| A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease | Q34526685 | ||
| Ferritin: a novel mechanism for delivery of iron to the brain and other organs. | Q34622902 | ||
| A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease | Q34658144 | ||
| Influence of neuromelanin on oxidative pathways within the human substantia nigra | Q34802086 | ||
| Long-lasting neural and behavioral effects of iron deficiency in infancy | Q34977210 | ||
| Iron misregulation in the brain: a primary cause of neurodegenerative disorders | Q35172307 | ||
| A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders | Q35212177 | ||
| Neuroferritinopathy in a French family with late onset dominant dystonia | Q35442453 | ||
| An iron-sulfur cluster plays a novel regulatory role in the iron-responsive element binding protein | Q35468837 | ||
| The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy | Q35545150 | ||
| Iron metabolism and the IRE/IRP regulatory system: an update | Q35754458 | ||
| The relevance of iron in the pathogenesis of Parkinson's disease. | Q35754511 | ||
| Occupational and environmental risk factors for Parkinson's disease | Q35791905 | ||
| Ubiquitin-proteasome system and Parkinson's diseases | Q35998400 | ||
| Hepcidin--a regulator of intestinal iron absorption and iron recycling by macrophages | Q36057889 | ||
| Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study | Q36144981 | ||
| Prevalence of haemochromatosis gene mutations in Parkinson's disease | Q36226909 | ||
| Metal ions and oxidative protein modification in neurological disease. | Q36294760 | ||
| Iron, neuroinflammation, and Alzheimer's disease | Q36322650 | ||
| TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis | Q36403570 | ||
| Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders | Q36664537 | ||
| Implications for estrogens in Parkinson's disease: an epidemiological approach. | Q36721786 | ||
| Developmental, regional, and cellular expression of SFT/UbcH5A and DMT1 mRNA in brain | Q38341285 | ||
| Relationship of iron to oligodendrocytes and myelination | Q41087116 | ||
| Neuropathology of Parkinson's disease | Q41095404 | ||
| Prevention of neuroleptic-induced dopamine D2 receptor supersensitivity by chronic iron salt treatment | Q41994164 | ||
| Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. | Q42470896 | ||
| Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains | Q42477389 | ||
| Microglial cells prevent nitric oxide-induced neuronal apoptosis in vitro | Q42540242 | ||
| Domain homologues of dopamine beta-hydroxylase and ferric reductase: roles for iron metabolism in neurodegenerative disorders? | Q42658403 | ||
| The specific vulnerability of the substantia nigra to MPTP is related to the presence of transition metals | Q43466545 | ||
| Glial cells contribute more to iron and aluminum accumulation but are more resistant to oxidative stress than neuronal cells | Q43509406 | ||
| Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure | Q43735123 | ||
| The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein | Q43798526 | ||
| Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat. | Q43825415 | ||
| Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T. | Q44034310 | ||
| The relationship between intracellular free iron and cell injury in cultured neurons, astrocytes, and oligodendrocytes. | Q44066996 | ||
| Ferritin induction protects cortical astrocytes from heme-mediated oxidative injury | Q44105509 | ||
| Coffee drinking influences plasma antioxidant capacity in humans. | Q44162829 | ||
| Risk tables for parkinsonism and Parkinson's disease. | Q44309519 | ||
| Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration | Q44365099 | ||
| Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease | Q44386905 | ||
| Adult nutrient intake as a risk factor for Parkinson's disease | Q44487546 | ||
| Iron-binding characteristics of neuromelanin of the human substantia nigra. | Q44542032 | ||
| Antioxidant and prooxidant properties of caffeine, theobromine and xanthine. | Q44576868 | ||
| Antioxidative activities of fractions obtained from brewed coffee | Q44753377 | ||
| Iron accumulation, iron-mediated toxicity and altered levels of ferritin and transferrin receptor in cultured astrocytes during incubation with ferric ammonium citrate. | Q44792347 | ||
| In vitro and ex vivo antihydroxyl radical activity of green and roasted coffee | Q44804830 | ||
| Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats | Q44848373 | ||
| Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. | Q44856789 | ||
| Characterization and modulation of the transferrin receptor on brain capillary endothelial cells | Q44923706 | ||
| Antioxidant behaviour of caffeine: efficient scavenging of hydroxyl radicals | Q44938311 | ||
| Electrochemical investigation into the redox activity of Fe(II)/Fe(III) in the presence of nicotine and possible relations to neurodegenerative diseases. | Q45036424 | ||
| Role of dietary iron restriction in a mouse model of Parkinson's disease | Q45142327 | ||
| Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. | Q45933973 | ||
| Polymorphisms in iron-responsive binding protein 2 and lack of association with sporadic Parkinson's disease | Q46372187 | ||
| Neuroprotection by iron chelator against proteasome inhibitor-induced nigral degeneration | Q46541429 | ||
| Hepcidin is decreased in TFR2 hemochromatosis | Q46624831 | ||
| Pooled analysis of tobacco use and risk of Parkinson disease | Q46785257 | ||
| Microglia and astroglia prevent oxidative stress-induced neuronal cell death: implications for aceruloplasminemia. | Q46814290 | ||
| Identification of a novel route of iron transcytosis across the mammalian blood-brain barrier | Q47239973 | ||
| Mutations in the hemochromatosis gene (HFE), Parkinson's disease and parkinsonism | Q47710928 | ||
| Screening for mutations of the IRP2 gene in Parkinson's disease patients with hyperechogenicity of the substantia nigra. | Q47839890 | ||
| Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes | Q47848377 | ||
| The significance of the mutated divalent metal transporter (DMT1) on iron transport into the Belgrade rat brain. | Q48116475 | ||
| Neonatal iron exposure induces neurobehavioural dysfunctions in adult mice | Q48135971 | ||
| Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra | Q48146389 | ||
| In vitro and in vivo studies investigating possible antioxidant actions of nicotine: relevance to Parkinson's and Alzheimer's diseases. | Q48178306 | ||
| Increased nigral iron content in postmortem parkinsonian brain | Q48182830 | ||
| Infusion of iron into the rat substantia nigra: Nigral pathology and dose‐dependent loss of striatal dopaminergic markers | Q48299583 | ||
| Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts. | Q48346436 | ||
| Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein | Q48386115 | ||
| Expression of the neuronal transferrin receptor is age dependent and susceptible to iron deficiency | Q48404946 | ||
| Manganese: a transition metal protects nigrostriatal neurons from oxidative stress in the iron-induced animal model of parkinsonism | Q48422450 | ||
| ??? | Q64789964 | ||
| Brain capillary endothelial cells mediate iron transport into the brain by segregating iron from transferrin without the involvement of divalent metal transporter 1. | Q48458370 | ||
| Trace element concentration in human brain. Activation analysis of cobalt, iron, rubidium, selenium, zinc, chromium, silver, cesium, antimony and scandium | Q48472892 | ||
| Iron induces degeneration of nigrostriatal neurons | Q48494836 | ||
| Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. | Q48502457 | ||
| Substantia nigra echogenicity is normal in non-extrapyramidal cerebral disorders but increased in Parkinson's disease | Q48573193 | ||
| Transferrin receptor on endothelium of brain capillaries | Q48602638 | ||
| Altered systemic iron metabolism in Parkinson's disease | Q48625403 | ||
| EPR investigations of the iron domain in neuromelanin. | Q48659091 | ||
| In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage | Q48829730 | ||
| Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits | Q48952359 | ||
| Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells | Q49016593 | ||
| Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation? | Q49019886 | ||
| The effect of age on the non-haemin iron in the human brain. | Q51318963 | ||
| Risk of Parkinson disease in women: effect of reproductive characteristics. | Q51940269 | ||
| Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. | Q52549517 | ||
| Environmental risk factors and Parkinson's disease: a metaanalysis. | Q52932783 | ||
| Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly. | Q53216133 | ||
| Deregulation of proteins involved in iron metabolism in hepcidin-deficient mice. | Q53926764 | ||
| The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems | Q54170347 | ||
| Distribution of divalent metal transporter 1 and metal transport protein 1 in the normal and Belgrade rat | Q54975411 | ||
| Inhibition of non-haem iron absorption in man by polyphenolic-containing beverages. | Q55034248 | ||
| Neuroferritinopathy | Q57316219 | ||
| Binding of a cytosolic protein to the iron-responsive element of human ferritin messenger RNA | Q57397581 | ||
| Gender differences in Parkinson's disease | Q57779630 | ||
| The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson's disease patients | Q60687066 | ||
| Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain | Q61714016 | ||
| In Vitro Antioxidant and ex Vivo Protective Activities of Green and Roasted Coffee | Q62111342 | ||
| Analysis of ferritin genes in Parkinson disease | Q62391452 | ||
| TorsinA accumulation in Lewy bodies in sporadic Parkinson's disease | Q64769140 | ||
| Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry | Q64861825 | ||
| Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. | Q67218564 | ||
| Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease | Q67228588 | ||
| Detection and isolation of a hepatic membrane receptor for ferritin | Q67277091 | ||
| Epidemiology of Parkinson's disease. | Q67401761 | ||
| Basal ganglia iron content in Parkinson's disease measured with magnetic resonance. | Q67405918 | ||
| [Environmental factors in the etiology of Parkinson's disease] | Q68546394 | ||
| Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine | Q71464560 | ||
| Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions | Q71894700 | ||
| Intranigral injected iron progressively reduces striatal dopamine metabolism | Q72232437 | ||
| Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease | Q72269342 | ||
| Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease | Q72319648 | ||
| Role of flavonoids and iron chelation in antioxidant action | Q72377049 | ||
| Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study | Q73370745 | ||
| Association study between iron-related genes polymorphisms and Parkinson's disease | Q74519525 | ||
| P433 | issue | 2 | |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 183-195 | |
| P577 | publication date | 2008-07-11 | |
| P1433 | published in | Neurobiology of Disease | Q15716606 |
| P1476 | title | Genetics of iron regulation and the possible role of iron in Parkinson's disease | |
| P478 | volume | 32 |
| Q39407652 | A mechanistic study of proteasome inhibition-induced iron misregulation in dopamine neuron degeneration |
| Q50279712 | AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α-synuclein oligomers |
| Q57962773 | An iron–dopamine index predicts risk of parkinsonian neurodegeneration in the substantia nigra pars compacta |
| Q92220413 | Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson's Disease: A Systematic Review |
| Q87560047 | Angiotensin II inhibits iron uptake and release in cultured neurons |
| Q36276511 | Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease |
| Q62780769 | Association study between four polymorphisms in the HFE, TF and TFR genes and Parkinson’s disease in Southern Italy |
| Q37729558 | Blood Transcriptomic Meta-analysis Identifies Dysregulation of Hemoglobin and Iron Metabolism in Parkinson' Disease |
| Q37605018 | Brain iron homeostasis: from molecular mechanisms to clinical significance and therapeutic opportunities |
| Q53181763 | C282Y and H63D Polymorphisms in Hemochromatosis Gene and Risk of Parkinson's Disease: A Meta-Analysis. |
| Q24630927 | Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century |
| Q50553843 | Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson’s disease |
| Q48377173 | Effects of decreased dopamine transporter levels on nigrostriatal neurons and paraquat/maneb toxicity in mice |
| Q37068758 | Effects of hemochromatosis and transferrin gene mutations on peripheral iron dyshomeostasis in mild cognitive impairment and Alzheimer's and Parkinson's diseases. |
| Q28731919 | Evaluation of brain iron content based on magnetic resonance imaging (MRI): comparison among phase value, R2* and magnitude signal intensity |
| Q48195020 | Expanded and Wild-type Ataxin-3 Modify the Redox Status of SH-SY5Y Cells Overexpressing α-Synuclein |
| Q42745591 | Hepcidin Plays a Key Role in 6-OHDA Induced Iron Overload and Apoptotic Cell Death in a Cell Culture Model of Parkinson's Disease |
| Q34798799 | Inhibition of Sirtuin 2 exerts neuroprotection in aging rats with increased neonatal iron intake |
| Q35202338 | Insulin resistance impairs nigrostriatal dopamine function |
| Q37821331 | Iron chelation and neuroprotection in neurodegenerative diseases |
| Q64279831 | Iron deposition in Parkinson's disease by quantitative susceptibility mapping |
| Q34427716 | Late-life hemoglobin and the incidence of Parkinson's disease |
| Q33708283 | Neurotoxic in vivo models of Parkinson's disease recent advances. |
| Q26746899 | Parkinson's Disease: The Mitochondria-Iron Link |
| Q38603331 | Parkinson's disease is associated with DNA methylation levels in human blood and saliva |
| Q48329843 | Parkinson's disease: diagnostic potential of high-resolution phase difference enhanced MR imaging at 3 T. |
| Q37671088 | Pooled analysis of iron-related genes in Parkinson's disease: association with transferrin |
| Q41440746 | Regulation of quinolinic acid neosynthesis in mouse, rat and human brain by iron and iron chelators in vitro |
| Q38164879 | Role of iron in UPS impairment model of Parkinson's disease |
| Q28681958 | Serum iron levels and the risk of Parkinson disease: a Mendelian randomization study |
| Q37824440 | Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no. |
| Q37077841 | Susceptibility-weighted MRI of extrapyramidal brain structures in Parkinsonian disorders |
| Q37343285 | Systems genetics analysis of iron regulation in the brain. |
| Q35750201 | T1rho and T2rho MRI in the evaluation of Parkinson's disease |
| Q44642015 | The PLA2G6 gene in early-onset Parkinson's disease |
| Q28396222 | The perplexing paradox of paraquat: the case for host-based susceptibility and postulated neurodegenerative effects |
Search more.